These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 8451463)

  • 1. Evaluating the risk of liver cancer in humans exposed to trichloroethylene using physiological models.
    Fisher JW; Allen BC
    Risk Anal; 1993 Feb; 13(1):87-95. PubMed ID: 8451463
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetic modeling of trichloroethylene and trichloroacetic acid in humans.
    Allen BC; Fisher JW
    Risk Anal; 1993 Feb; 13(1):71-86. PubMed ID: 8451462
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Applying mode-of-action and pharmacokinetic considerations in contemporary cancer risk assessments: an example with trichloroethylene.
    Clewell HJ; Andersen ME
    Crit Rev Toxicol; 2004; 34(5):385-445. PubMed ID: 15560567
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Physiologically based pharmacokinetic modeling of the pregnant rat: a multiroute exposure model for trichloroethylene and its metabolite, trichloroacetic acid.
    Fisher JW; Whittaker TA; Taylor DH; Clewell HJ; Andersen ME
    Toxicol Appl Pharmacol; 1989 Jul; 99(3):395-414. PubMed ID: 2749729
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Trichloroethylene cancer risk: simplified calculation of PBPK-based MCLs for cytotoxic end points.
    Bogen KT; Gold LS
    Regul Toxicol Pharmacol; 1997 Feb; 25(1):26-42. PubMed ID: 9056499
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A trichloroethylene risk assessment using a Monte Carlo analysis of parameter uncertainty in conjunction with physiologically-based pharmacokinetic modeling.
    Cronin WJ; Oswald EJ; Shelley ML; Fisher JW; Flemming CD
    Risk Anal; 1995 Oct; 15(5):555-65. PubMed ID: 7501875
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Physiologically based pharmacokinetic modeling of the lactating rat and nursing pup: a multiroute exposure model for trichloroethylene and its metabolite, trichloroacetic acid.
    Fisher JW; Whittaker TA; Taylor DH; Clewell HJ; Andersen ME
    Toxicol Appl Pharmacol; 1990 Mar; 102(3):497-513. PubMed ID: 2315918
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Estimating the risks of liver and lung cancer in humans exposed to trichloroethylene using a physiological model.
    Fisher JW
    Toxicol Lett; 1993 May; 68(1-2):127-9. PubMed ID: 8516759
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dose-response analyses of the carcinogenic effects of trichloroethylene in experimental animals.
    Rhomberg LR
    Environ Health Perspect; 2000 May; 108 Suppl 2(Suppl 2):343-58. PubMed ID: 10807564
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Physiologically based pharmacokinetic modeling with trichloroethylene and its metabolite, trichloroacetic acid, in the rat and mouse.
    Fisher JW; Gargas ML; Allen BC; Andersen ME
    Toxicol Appl Pharmacol; 1991 Jun; 109(2):183-95. PubMed ID: 2068722
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Trichloroacetic acid: updated estimates of its bioavailability and its contribution to trichloroethylene-induced mouse hepatomegaly.
    Chiu WA
    Toxicology; 2011 Jul; 285(3):114-25. PubMed ID: 21549800
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of an updated PBPK model for trichloroethylene and metabolites in mice, and its application to discern the role of oxidative metabolism in TCE-induced hepatomegaly.
    Evans MV; Chiu WA; Okino MS; Caldwell JC
    Toxicol Appl Pharmacol; 2009 May; 236(3):329-40. PubMed ID: 19249323
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A physiologically based pharmacokinetic model for trichloroethylene in the male long-evans rat.
    Simmons JE; Boyes WK; Bushnell PJ; Raymer JH; Limsakun T; McDonald A; Sey YM; Evans MV
    Toxicol Sci; 2002 Sep; 69(1):3-15. PubMed ID: 12215655
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Physiological pharmacokinetic modeling of inhaled trichloroethylene in rats.
    Dallas CE; Gallo JM; Ramanathan R; Muralidhara S; Bruckner JV
    Toxicol Appl Pharmacol; 1991 Sep; 110(2):303-14. PubMed ID: 1891776
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tissue dosimetry expansion and cross-validation of rat and mouse physiologically based pharmacokinetic models for trichloroethylene.
    Keys DA; Bruckner JV; Muralidhara S; Fisher JW
    Toxicol Sci; 2003 Nov; 76(1):35-50. PubMed ID: 12915716
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Key scientific issues in the health risk assessment of trichloroethylene.
    Chiu WA; Caldwell JC; Keshava N; Scott CS
    Environ Health Perspect; 2006 Sep; 114(9):1445-9. PubMed ID: 16966103
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Trichloroethylene risk assessment: a review and commentary.
    Jollow DJ; Bruckner JV; McMillan DC; Fisher JW; Hoel DG; Mohr LC
    Crit Rev Toxicol; 2009; 39(9):782-97. PubMed ID: 19852561
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Presystemic elimination of trichloroethylene in rats following environmentally relevant oral exposures.
    Liu Y; Bartlett MG; White CA; Muralidhara S; Bruckner JV
    Drug Metab Dispos; 2009 Oct; 37(10):1994-8. PubMed ID: 19581386
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Physiologically based pharmacokinetic models for trichloroethylene and its oxidative metabolites.
    Fisher JW
    Environ Health Perspect; 2000 May; 108 Suppl 2(Suppl 2):265-73. PubMed ID: 10807557
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Considering pharmacokinetic and mechanistic information in cancer risk assessments for environmental contaminants: examples with vinyl chloride and trichloroethylene.
    Clewell HJ; Gentry PR; Gearhart JM; Allen BC; Andersen ME
    Chemosphere; 1995 Jul; 31(1):2561-78. PubMed ID: 7670867
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.